SCHEDULE: Arcellx Merger Complete: Gilead Acquires Company for $115/Share Plus CVR

Arcellx, Inc. has been acquired by Gilead Sciences, Inc. through a tender offer and subsequent merger, with shareholders receiving $115 per share plus a contingent value right.

Summary

• Arcellx, Inc. has been acquired by Gilead Sciences, Inc. via a tender offer and merger, which closed on April 28, 2026.
• The acquisition involved a tender offer for all outstanding common stock at $115.00 per share in cash, plus one contingent value right (CVR) per share.
• The CVR entitles shareholders to a potential additional milestone payment of $5.00 per CVR.
• Following the tender offer, a merger was completed, with Arcellx becoming a wholly-owned subsidiary of Gilead.
• Outstanding stock options and restricted stock units (RSUs) were converted into cash payments and CVRs, based on the merger consideration.
• Rami Elghandour, the reporting person, has ceased to beneficially own any shares of Arcellx common stock following the closing of the merger.
• All previously reported beneficial ownership by Rami Elghandour is now zero.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive outcome for Arcellx shareholders, as the acquisition price represents a substantial premium and includes a contingent payment, indicating a successful exit.

Positives

• Shareholders received a significant cash payment of $115.00 per share.
• The inclusion of a CVR offers potential for additional upside if specified milestones are achieved.
• The transaction provides a clear exit for shareholders and a definitive end to the company's public trading status.

Negatives

• The company will no longer operate as an independent entity.
• The potential additional $5.00 per share from the CVR is contingent on future milestone achievement, providing no certainty of additional payment.

Risks

• The achievement of the milestone payment associated with the CVR is not guaranteed.
• The filing does not detail the specific milestone required for the CVR payment, creating uncertainty for recipients.

Future Outlook

The future outlook for Arcellx, Inc. is now as a wholly-owned subsidiary of Gilead Sciences, Inc. The primary future event for former shareholders is the potential achievement of the milestone tied to the CVR, which would result in an additional $5.00 per share payment.

Management Comments

• The Reporting Person tendered all shares of common stock held by him in the Offer.
• Following the Closing Date, the Reporting Person ceased to beneficially own any shares of common stock.

Industry Context

StockSavvy.ai notes that this acquisition by Gilead Sciences, Inc. of Arcellx, Inc. aligns with the broader trend of large pharmaceutical companies acquiring innovative biotechnology firms to bolster their pipelines, particularly in areas like cell therapy, which Arcellx is known for.

Stakeholder Impact

• Shareholders: Receive $115.00 per share in cash plus a CVR, providing a significant return and potential for further upside.
• Employees: Transition to employment under Gilead Sciences, Inc., with potential changes in roles and benefits.
• Creditors: The merger likely involves the assumption of Arcellx's liabilities by Gilead, with terms to be managed by the acquiring entity.
• Suppliers: Business relationships may be integrated or altered under Gilead's procurement policies.

Next Steps

• Shareholders to receive the merger consideration ($115.00 cash plus CVR).
• Monitoring for the achievement of the milestone associated with the CVR to determine if the additional $5.00 payment will be made.

Key Dates

Recommendation

For existing Arcellx shareholders, the transaction has closed, and they have received the merger consideration. The recommendation is 'hold' for the CVR, as its value is contingent on future events. For potential investors looking at Gilead, this acquisition is a strategic move that should be evaluated within Gilead's broader portfolio and growth strategy.

Keywords

Arcellx, Gilead Sciences, Merger, Acquisition, Tender Offer, Contingent Value Right, CVR, Schedule 13D, SEC Filing, Biotechnology, Pharmaceuticals